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~"~'~ Rota Erdothelin In A Rat Model of  o f  Endogenous 
Chronic Heart Failure: Long-term Effects o f  the 
Endothelin Antagonist Besenten 
Paul Mulder, Vincent Richard, Jean-Paul Henry, Francolse Lallemand, 
Christian Thuillas. Dept of Pharmacology (VACOM=,D, IFRMP no 23), 
Rouen University Medical School, Rouen, France 
Although plasma levels of endothelin lET) are elevated in chronic heart 
failure (CHF), the role of this vasoconstrictor peptide in the long-term cardio- 
vascular changes induced by CHF is not known. Thus, we investigated the 
effects of chronic (9 months) treatment with the mixed ET^-ETB antagonist 
bossntan less, 30 mg/kg/day), administered alone or in combination with the 
angiotansin converting enzyme inhibitor cilazapfil (Cil, 10 mg/kg/day), and 
compared these effects to those induced by Cil alone. CHF was induced in 
rats by left coronary artery ligation, and treatments were administered in rat 
chow, starting 7 days after ligation (n = 60 per group). After 9 months, mean 
artedal pressure (MAP), left vantdcular (LV) systolic pressure (LVSP), LV 
end diastolic pressure (LVEDP, mm Hg), and LV dP/dt (10 amm Hg/sec) were 
measured in anesthetized rats. Table shows survival (%), hemodynamics, 
heart weight (HW, g) and cardiac collagen density (Coil; %); 
Survival MAP LVSP LVEDP dP/dt HW Cod 
Control 43 1184-4 137±5 94-1 6.94-0.4 1.81 4-0.05 3.34-0.2 
Cil 77* 93=1:4" 1034-5" 54-1" 0.64-0.3 1.444-0.04" 2.24-0.1" 
Sos 44 1154-3 1254-6 84-2 6.44-0.51.874-0.06 3.44-0.1 
Bos+Cil 80* 824-2t* 05±3" 4±1'* 5.24-0.4 1.524-0.06" 2.04-0.1 * 
*p < 0.05 vs Control;i'p < 0.05 vs Oil (n = 13-24 per gr(,up) 
Thus, in this rat model of CHF, ET plays a role in the maintenance of 
arterial blood pressure, which can be unmasked by chronic treatment with 
an angiotsnsin converting enzyme inhibitor. However, long term treatment 
with an El" antagonist does not affect sunlival, cardiac hemodynamics, or 
cardiac remodeling and does not display any additive effect to those of an 
angiotsnsln converting enzyme inhibitor on these parameters. 
[ " ~  Angiotensln II Receptor Subtypes in Failing and 
Non-Fail ing HUMan Hearts: Analysis of  Gene 
Expression 
G.A, Hsywond, L. Gullestad, T. Katsuya, H. Hutchinson, R. Pratt, 
M. Hoduchi, M.B. Fowler. Division of Cardiovascular Medicine, Stanford 
University, Stanford, CA 
Antagonism of anglotensin II at the receptor level, is a focus of intense 
interest in the pharmacological management of heart failure. It has been 
reported that heart failure induces changes in the level of gane expression 
for beth the ATI and AT2 receptors, however there Is disagreement over 
the nature and magnitude of such changes. We used competitive reverse 
transcription-palymerase chain reaction (RT~PCR) to measure the direction 
and magnitude of changes in mRNA expression for both receptor subtypes 
in human myocardial biopsies. Vanfficular biopsies were obtained from 12 
patients with end-stage heart failure at the time of cardiac transplantation 
(dilated cardiomyopathy n = 7, Ischemlc heart disease n = 5), and from 9 
non-falling donor hearts. Synthetic mRNA 'mimics' were constructed using a 
PCR based technique and functioned as internal standards dudng RT-PCR. 
Oflgonucieotide pdmers specific for each target gene and it's synthetic mRNA 
'mimic' were used to co-amplify the target germ against a ditutional ssdss of 
the appropriate 'mimic'. 
Results: AT1 gone expression decreased 2.5 fold (p = 0.015) in failing 
hearts compared with non-falling donor hearts. There was no significant 
difference in AT2 germ expression. 
Conclusions: This change in the expression of the two anglotansln receptor 
subtypes defines the mechanism ddving the altered receptor populations in 
heart failure. This shift in gene expression has important implications for the 
use of selective AT1 antagonists uch as Losartan. 
~ Hemodynsmlc Effects of the Endothelln-1 
Receptor Antagonist Boesnten At Different Stages 
of  Heart Failure In Conscious Dogs 
R(~mi Choussat, Fabrics Bad)e, Jinbo Su, Genevieve Malstre, 
Alaln Carayon, Bertrand Crozatler, Luc Hittinger. INSERM U400, Fac. de 
Mad., Cr~teil, and Service de Biochimie, CHU Pitid, Paris, France 
Endothelln-1 (ET) inhibition by El" antagonist is a potential therapy in severe 
heart failure, however, the effect of ET inhibition in the early stage of heart 
failure has not been evaluated. Therefore, we examined the acute hemody- 
namlc effects of the mixed (ETA & ETa) receptor antagonist besentan (Bas) 
at different stages of heart failure induced by dght vantricular (RV) pacing 
(250 bpm) In conscious dogs. Nine dogs were chronically Instrumented for 
the measurements of left ventdcufar pressure and its first derivative (dP/dt), 
cardiac output, regional wall thickness and aortic pressure. Boa (3 mg/kg, 
iv bolus) and placebo were given at control (C), at a stage of LV vantricular 
dysfunction with perserved cardiac output (1 week of RV pacing: Wl) and in 
an advanced phase of heart failure with low cardiac output (3 weeks of RV 
pacing: W3). With the development of hear failure, baseline plasma El" level 
increased progressively (C: 1.0 4- 0.7, Wl: 2.5.4- 1.5, W3:3.3 4.1.7 pg/ml, 
p < 0.05). After Bos, plasma ET increased to a similar extent at all stages, 
suggesting similar levels of blockade. Placebo did not induce hemndynamic 
and plasma ET changes dudng the 30 m!n recording at any stage. At con- 
trol, Bas did not change hemodynamice. At W1 and W3 of RV pacing, Bos 
reduced mean arterial pressure (7 4- 2 and 8 4- 1 mm Hg respectively, p < 
0.005) and increased stroke volume only at W3. At control and dudng the 
development of heart failure, Bos did not modifly significantly LV dPIdt nor 
regional wall thickening. At W3, an addltlonnal bolus of Bos 10 mg/kg did 
not produce further hemodynamic effects. Thus, at a stage of LV dysfunction 
with presenred cardiac ouJput endothelin participates in the maintenance of 
artadal pressure. In the advanced phase of heart fal!ure with low cardiac 
output, ET inhibition by ET antagonist bosentan improves cardiac function 
through systemic hemodynamic mprovement. 
~"~9"~ Anglcteneln II Antagonist  Improves the 
I, tamodynamlcs and Renal Functions in the 
Development of  Congest ive Heart Failure 
Yukiharu Meeds, Atsuyuki Wada, Takayoshi Tsutamofo, Dalsuke Fukal, 
Keiko Maeda, Masato Ohnishi, Tomoko Hisanaga, Masahiko Kinoshita. 
Shiga University of Medical Science, Otsu, Japan 
The angiotansln converting enzyme inhibitor is widely used on the patients 
with congestive heart failure (CHF), however, whether the direct inhibitidn 
of endogenous anglotsnsin II has beneficial effects in preventing the de- 
velopment of CHF has not been fully clarified. Therefore, we examined to 
what extent chronic treatment with an aogiotenaln II antagonist, TCV-116 
('I'CV), prevents the detsrioration of CHF, we chronically administered TCV 
(3 mg/kg/day) orally to the dogs with CHF induced by rapid vantrlcutar pacing 
(RVP) at 270 bpm. The vehicle group (n = 6), RVP for 22 days received no 
treatment and the TCV group (n = 6), RVP for 22 days received TCV for 14 
days beginning 8 days after the initiation of RVP. 
Vehicle TCV 
Baseline After Baseline After 
AOP (mmHg) 1144-2 884-3" 1194-8 934-3, 
PCWP (mmHg} 0.5 4- 0.8 10.~4-1.8" 1.8 4- 0.6 15.0:1:1.3" 
CO (I/rain) 3.04-0.2 1.74-0.1" 2.54-0.1 2.24-0.1 "# 
NE (pg/ml) 1904- 30 773 4- 96" 2704- 25 464 4- 77# 
U-VoI (ml/mln) 1.0±0.I 0A4- 0.1" 0.94-0.1 1.14-0.3 # 
U-Na (~Eo,/mln) 61 ±20 284-8* 484-10 744-16 # 
GFR (mPmln) 75 ± 2 314- 7" 56 4- 5 52 4- 4 e 
RPF (mVmln) 2244-14 844-19" 2214-11 1874-19 # 
AOP: mean aortic pressure, POWP: pulmonary c~oillary wedge pressure, CO: cardiac 
output, NE: plasma norepinephrine, U-Voh urinary flow rate, U-Na: urinary sodium excre- 
tion rate, GFR: gtomeNlar filtration rate. RPF: renal plasma flow, *P < 0.05 vs Baseline, 
#P < 0.05 vs Vehicle. 
In the vehicle group, severe CHF was induced charastsrized by significant 
reduction of CO and renal functions, with ascites and respiratory distress. 
Chronic treatment with TCV signHtcantly prevented the reduction of CO, 
udcary water and sodium excretion and suppressed the increase of NE 
secretion. These findings uggest hat chronic direct inhibition of endogenous 
anglotansin ti activity prevents the volume retention and activation of the 
sympathetic nervous system. 
~ R o l e  of  Endogenous Atrial Nstrgurstlc Peptlde 
Alter Chronic InhlbPtlon o f  Anglotensin II Activity 
In Heart Failure 
Atsuyukl Wade, Yukiharo Meeds, Dalsuke Fukai, Masafo Ohnishi, 
Kelko Maeda, Tomoko HIsanaga, Takayoshi Tsutamoto, 
Masabiko Kinoshita. Shlga University of Medical Science, Ohtsu, JaDe:, 
To elucidate the pathophyslologlcal role of endogenous atrial natdurotic pup- 
tide (ANP) after chronic inhibition of angtotansln (An[]) II activity in heart 
failure, we used HS-142-1 (HS, 3 mg/kg), a specific antagonist for the ANP 
guanylate cyclase coupled receptor, to dogs with heart failure induced by 
rapid right ventricular pacing (270 ppm, 22 days) after chronic administration 
of an Ang II antagonist, TCV-116 (TCV, 3 mg/kg/day, for 14 days), 
Chronic treatment with TCV attenuated the decreases in cGMP, U-V and 
U-Na and the elevation of RAR Although HS significantly suppressed the 
plasma cGMP levels in beth groups, PCWP and RAP were significantly 
increased only in the TCV-treated dogs. On the other hand, U-V and U= 
Na were decreased in beth groups. These findings suggest that chronic 
inhibition of Ang II activity improves the blunted vasodilative action of ANP 
